IP Library Granted Patent US 9,926,273
Granted Patent B2
US 9,926,273 · App. 14/015,030 · Granted Mar 27, 2018

Composition and methods for modulating a kinase cascade

Inventor: David G. Hangauer, Jr. (Lancaster, NY)
Assignee: Athenex, Inc.
C07D213/56C07C303/32C07C309/29
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,926,273
App. No.
14/015,030
Granted
Mar 27, 2018
Kind
B2
Abstract

The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.

Claims (11)

1. A composition comprising a benzenesulfonate salt of compound 1:

or a pharmaceutically acceptable solvate or hydrate thereof, wherein the benzenesulfonate salt of compound 1 has a purity greater than 98.0% as determined by HPLC.

2. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier or excipient.

3. The composition of claim 1 , wherein compound 1 has a purity of 98.5% as determined by HPLC.

4. The composition of claim 1 , wherein compound 1 has a purity of 99.0% as determined by HPLC.

5. The composition of claim 1 , wherein compound 1 has a purity of 99.5% as determined by HPLC.

6. The composition of claim 1 , wherein compound 1 has a purity of 99.6% as determined by HPLC.

7. The composition of claim 1 , wherein compound 1 has a purity of 99.7% as determined by HPLC.

8. The composition of claim 1 , wherein compound 1 has a purity of 99.8% as determined by HPLC.

9. The composition of claim 1 , wherein compound 1 has a purity of 99.9% as determined by HPLC.

10. The composition of claim 1 , wherein compound 1 contains less than 250 ppm ethyl chloride.

Assignments (6)
SECURITY INTEREST Recorded Jun 22, 2020
From: ATHENEX, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 053005/0657 →
RELEASE OF SECURITY INTEREST Recorded Jun 19, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ATHENEX, INC.
Reel/Frame 052990/0677 →
PATENT SECURITY AGREEMENT Recorded Jul 3, 2018
From: ATHENEX, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047247/0812 →
CHANGE OF NAME Recorded Sep 21, 2015
From: KINEX PHARMACEUTICALS, INC.
To: ATHENEX, INC.
Reel/Frame 036644/0296 →
CHANGE OF NAME Recorded Sep 10, 2015
From: KINEX PHARMACEUTICALS, LLC
To: KINEX PHARMACEUTICALS, INC.
Reel/Frame 036585/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2013
From: HANGAUER, DAVID G., JR.
To: KINEX PHARMACEUTICALS, LLC
Reel/Frame 031382/0159 →
Continuity (3)
Provisional Application 61695100 · Aug 30, 2012
Provisional Application 61779868 · Mar 13, 2013
Related Publication 20140066445A1 · Mar 6, 2014